Skip to main content

Table 1 Baseline demographic and clinicopathologic findings

From: Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

  All patients (n = 55) Insulin resistance p
Yes (n = 30) No (n = 25)
Age (median) (min-max) 48.5 (27–80) 52 (29–80) 45 (27–66) 0.06
BMI (median) (min-max) 29.6 (18.9–43.4) 33.25 (18.92–43.4) 27.01 (21–35.2) 0.01
Waist circumference (cm) 100 (56–116) 100 (56–116) 89 (56–106) 0.7
Hip circumference (cm) 108 (58–134) 110 (58–134) 106 (95–120) 0.5
Fasting glucose level (mg/dl) 99 (72–125) 103 (82–125) 91 (72–115) 0.003
HDL (mg/dl) 57 (24–96) 55 (24–83) 59 (40–96) 0.07
LDL (mg/dl) 124 (51–219) 120 (51–198) 139 (61–219) 0.6
Total cholesterol (mg/dl) 215 (117–314) 205 (117–298) 218 (127–314) 0.5
Trigliseride (mg/dl) 98 (56–467) 121 (58–467) 89 (56–164) 0.007
Metabolic syndrome Yes 22 (40%) 17 (57%) 5 (20%) 0.006
No 33 (60%) 13 (43%) 20 (80%)
Menopause status (n) (%) Pre-menopause 32 (58%) 16 (53%) 16 (69%) 0.4
Post-menopause 23 (42%) 14 (47%) 9 (31%)
Clinical stage 2A 9 (16%) 7 (23%) 2 (8%) 0.2
2B 18 (32%) 10 (33%) 8 (32%)
3A 20 (36%) 8 (27%) 12 (48%)
3B 7 (14%) 5 (17%) 2 (8%)
3C 1 (2%) 0 (0%) 1 (4%)
Pathologic subtype Invazive ductal 44 (80%) 26 (87%) 18 (72%) 0.8
Invazive lobular 5 (9%) 1 (3%) 4 (16%)
Others 6 (11%) 3 (10%) 3 (12%)
Receptor status HR+, HER-2− 31 (56%) 17 (56%) 14 (56%) 0.7
HR−, HER-2+ 7 (13%) 5 (16%) 2 (8%)
HR+, HER-2+ 9 (16%) 4 (14%) 5 (20%)
HR−, HER-2− 8 (15%) 4 (14%) 4 (16%)
Hormone receptor status ER + PR+ 31 (56%) 18 (60%) 13 (52%) 0.9
ER + PR− 9 (16%) 3 (10%) 6 (24%)
ER − PR+ 0 (0%) 0 (0%) 0 (0%)
Ki 67 index ≤ 15 13 (24%) 11 (37%) 2 (8%) 0.01
> 15 42 (76%) 19 (63%) 23 (92%)
Pathological response CR 16 (29%) 5 (16%) 11 (44%) 0.02
Non-CR 39 (71%) 25 (84%) 14 (56%)
  1. HDL high-density lipoprotein, LDL low-density lipoprotein, HR hormone receptor, Her-2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor